Jason Greenfield, MD
Urology · Lone Tree, CONPI 1659385268
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (28.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Endo Pharmaceuticals Inc. at 52.6% of the total. Reporting peaked in 2019 at $15,050 and has fallen 96.6% since, to $508 in 2025.
Across 173 payments — averaging $111.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$10K
- Boston Scientific$2K
- Coloplast$2K
- Gyrus ACMI, Inc.$2K
- Teleflex LLC$960
- Astellas Pharma US Inc$447
- plus $2K from 36 others
What the payments were for
- Consulting fees$5,09826%
- Speaking & faculty fees$5,45028%
- Travel & lodging$3,03416%
- Food & beverage$4,58224%
- Education$1,1596%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 28 | $10,164 |
| Boston Scientific | 22 | $2,249 |
| Coloplast | 12 | $1,635 |
| Gyrus ACMI, Inc. | 1 | $1,548 |
| Teleflex LLC | 5 | $960 |
| Astellas Pharma US Inc | 19 | $447 |
| Procept Biorobotics Corporation | 2 | $297 |
| Bayer | 8 | $155 |
| Dendreon Pharmaceuticals LLC | 5 | $148 |
| Sumitomo Pharma America, Inc. | 6 | $144 |
| Johnson & Johnson | 2 | $136 |
| Neotract Inc. | 2 | $129 |
| Ferring Pharmaceuticals Inc. | 6 | $118 |
| 180 Medical, Inc. | 5 | $111 |
| Amgen | 6 | $109 |
| Axonics, Inc. | 5 | $104 |
| Uromedica, Incorporated | 1 | $100 |
| Pfizer | 5 | $95 |
| Medtronic | 1 | $74 |
| Blue Earth Diagnostics | 4 | $67 |
| Merck | 3 | $54 |
| Progenics Pharmaceuticals, Inc. | 2 | $47 |
| Myovant Sciences Inc. | 2 | $42 |
| Laborie Medical Technologies Corp. | 2 | $34 |
| Ambu Inc. | 1 | $32 |
| Sanofi | 1 | $28 |
| Urogen Pharma, Inc. | 2 | $26 |
| Novartis | 1 | $26 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $24 |
| Immunitybio, Inc. | 1 | $23 |
| Cook Medical LLC | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Steris Corporation | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| BD | 1 | $16 |
| Rochester Medical Corporation | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Hollister Incorporated | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$9,405
- UGN Laser Capital$1,548
- TITAN$1,122
- UroLift$727
- GENERAL - THERAPIES$700
- AMS$664
- VIRTUE$320
- AquaBeam Robotic System$165
- AQUABEAM SYSTEM$132
- ADVANCE$124
- GENERAL ONCOLOGY$119
- ProACT$100
How this compares
$19,322 in reported general payments places this provider in the 85th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 38 | $28,879 |
| GemtesaVibegron | 13 | $10,702 |
| Tamsulosin Hcl | 304 | $3,309 |
| Testosterone Cypionate | 67 | $2,159 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 59 | $1,097 |
| Trimethoprim | 12 | $1,042 |
| Finasteride | 83 | $950 |
| Cephalexin | 21 | $400 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $128 |
| Dutasteride | 15 | $94 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $79 |
| Ciprofloxacin Hcl | 28 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $447 | $28,87938 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $144 | $10,70213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 urology providers in Colorado.
Other urology in Lone Tree
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
- Nicholas WestfallGrand Junction$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.